+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Somatostatin Receptor Type 4 - Pipeline Review, H1 2020

  • ID: 5017445
  • Drug Pipelines
  • March 2020
  • Region: Global
  • 38 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Eli Lilly and Co
  • GlyTech Inc
  • Peptide Logic LLC
  • MORE
Somatostatin Receptor Type 4 - Pipeline Review, H1 2020

Summary

According to the recently published report 'Somatostatin Receptor Type 4 - Pipeline Review, H1 2020'; Somatostatin Receptor Type 4 (SSTR4) pipeline Target constitutes close to 5 molecules.

Somatostatin Receptor Type 4 (SSTR4) - Somatostatin receptor type 4 is a protein encoded by the SSTR4 gene. The activity of receptor is mediated by G proteins which inhibits adenylyl cyclase. It mediates antiproliferative action of somatostatin in tumor cells. It is functionally coupled to inhibition of adenylate cyclase and activation of both arachidonate release and mitogen-activated protein (MAP) kinase cascade.

The report 'Somatostatin Receptor Type 4 - Pipeline Review, H1 2020' outlays comprehensive information on the Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2 and 1 respectively. Report covers products from therapy areas Hormonal Disorders, Central Nervous System, Metabolic Disorders and Oncology which include indications Acromegaly, Inflammatory Pain, Mixed Pain (Nociceptive Pain/Neuropathic Pain), Neuroendocrine Tumors, Neuropathic Pain (Neuralgia), Pain and Pituitary ACTH Hypersecretion (Cushing Disease).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Somatostatin Receptor Type 4 (SSTR4)
  • The report reviews Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics
Reasons to Buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Somatostatin Receptor Type 4 (SSTR4)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Somatostatin Receptor Type 4 (SSTR4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Eli Lilly and Co
  • GlyTech Inc
  • Peptide Logic LLC
  • MORE
  • Introduction
  • Report Coverage
  • Somatostatin Receptor Type 4 (SSTR4) - Overview
  • Somatostatin Receptor Type 4 (SSTR4) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Somatostatin Receptor Type 4 (SSTR4) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Somatostatin Receptor Type 4 (SSTR4) - Companies Involved in Therapeutics Development
  • Eli Lilly and Co
  • GlyTech Inc
  • Peptide Logic LLC
  • Strongbridge Biopharma plc
  • Somatostatin Receptor Type 4 (SSTR4) - Drug Profiles
  • CNTX-0290 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Monoclonal Antibody Conjugate to Agonize SSTR4 for Pain - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Synthetic Peptides to Agonize Somatostatin Receptors for Acromegaly - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • veldoreotide ER - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • veldoreotide IR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Somatostatin Receptor Type 4 (SSTR4) - Dormant Products
  • Somatostatin Receptor Type 4 (SSTR4) - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
List of Tables
  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Indication, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pipeline by Eli Lilly and Co, H1 2020
  • Pipeline by GlyTech Inc, H1 2020
  • Pipeline by Peptide Logic LLC, H1 2020
  • Pipeline by Strongbridge Biopharma plc, H1 2020
  • Dormant Products, H1 2020
  • Dormant Products, H1 2020 (Contd..1), H1 2020
  • Dormant Products, H1 2020 (Contd..2), H1 2020
List of Figures
  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Top 10 Indications, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Eli Lilly and Co
  • GlyTech Inc
  • Peptide Logic LLC
  • Strongbridge Biopharma plc
Note: Product cover images may vary from those shown
Adroll
adroll